Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Update

Gain Therapeutics, Inc. (NASDAQ:GANX) was the target of a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 149,600 shares, a growth of 8.3% from the March 31st total of 138,100 shares. Based on an average daily volume of 158,200 shares, the days-to-cover ratio is currently 0.9 days. Currently, 1.1% of the company’s shares are sold short.

Insider Transactions at Gain Therapeutics

In other Gain Therapeutics news, Director Jeffrey Scott Riley acquired 30,000 shares of the company’s stock in a transaction dated Thursday, March 28th. The stock was bought at an average price of $3.86 per share, with a total value of $115,800.00. Following the completion of the transaction, the director now directly owns 30,000 shares of the company’s stock, valued at $115,800. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 11.00% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on GANX shares. HC Wainwright reiterated a “buy” rating and issued a $9.00 target price on shares of Gain Therapeutics in a research note on Thursday, April 25th. Chardan Capital restated a “buy” rating and issued a $6.00 price target on shares of Gain Therapeutics in a report on Wednesday, March 27th. Finally, Oppenheimer reiterated an “outperform” rating and set a $9.00 price objective on shares of Gain Therapeutics in a research note on Tuesday, April 23rd.

Gain Therapeutics Stock Down 2.3 %

Shares of Gain Therapeutics stock traded down $0.07 during trading hours on Tuesday, hitting $2.93. 34,753 shares of the company’s stock traded hands, compared to its average volume of 151,527. Gain Therapeutics has a twelve month low of $2.00 and a twelve month high of $5.65. The company has a market cap of $47.52 million, a PE ratio of -1.71 and a beta of 0.43. The company has a quick ratio of 3.59, a current ratio of 3.59 and a debt-to-equity ratio of 0.04. The stock has a 50 day simple moving average of $3.90 and a 200-day simple moving average of $3.44.

Gain Therapeutics (NASDAQ:GANX) last issued its quarterly earnings data on Tuesday, March 26th. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.03. Equities research analysts anticipate that Gain Therapeutics will post -1.22 earnings per share for the current fiscal year.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.